Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone and Vasopressin in Post-Resuscitation Syndrome
NCT04591990Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2021
- Primary completion
- Dec 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vasopressin and hydrocortisone in post-cardiac arrest syndrome (PCAS) (4 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Neurological outcome at 30 days. Started May 2021; status: recruiting.
02
Drugs
vasopressinhydrocortisone
03
Conditions
post-cardiac arrest syndrome (PCAS)
Beyond the preview
Go deeper on NCT04591990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04591990.